Loading
GB
GRI BIO, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Kelly Leanne M., was filed 04 Jun 2021.
GRI BIO, Inc.: what insiders have been doing
GRI BIO, Inc., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Nothing new has been filed by managers of GRI BIO, Inc. in twelve months, the latest record being from 24 April 2023.
The full history, which starts in 2021, counts 6 purchases against no sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
14
Thresholds
n/a
Buy Volume
€85,996
6 ops. · all time
Sell Volume
n/a
n/a
Since the insiders bought
- -89.1%Entry US$5,626,748.50 · Close at T+365 US$614,654.06
- -85.7%Entry US$5,197,920.00 · Close at T+365 US$740,703.63
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate GRI BIO, Inc. Strong Buy (bullish), based on 2 analysts. Average price target: US$18.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.38
Analyst consensus
2 analystsStrong buy
US$10.00Target US$18.50(+1241%)US$27.00
Income statement
EBITDA-US$12M
Net income-US$12M0.0% margin
Valuation
PER (trailing)0.0x
PER (forward)-0.7x
P/Book0.3x
Beta-0.61
Balance sheet & cash
Market capUS$3M
Total debtUS$71k
Free Cash Flow-US$10.2M
Debt / Equity0%
Profitability & ownership
ROE-142.0%
ROA-70.9%
% insiders0.4%
% institutions4.3%
Last declaration on 24 April 2023
Declarations14 total
172,189 sharesCommon StockSEC:0001824293-23-000102:0
385,510 sharesCommon StockSEC:0001824293-23-000104:0
172,189 sharesCommon StockSEC:0001824293-23-000103:0
28,517 shares0Common StockSEC:0001824293-22-000082:0
38,023 shares0Common StockSEC:0001824293-22-000061:0
1,085 shares@ US$4.0517.5% of flowCommon StockSEC:0001104659-21-076998:1
Canonical exit: 1 Sept 2021 (T+90)
1,508 shares@ US$4.0824.5% of flowCommon StockSEC:0001104659-21-076998:2
Canonical exit: 2 Sept 2021 (T+90)
3,657 shares@ US$4.00100.0% of flowCommon StockSEC:0001104659-21-076998:0
Canonical exit: 31 Aug 2021 (T+90)
6,800 shares@ US$4.5042.7% of flowCommon StockSEC:0001104659-21-073495:1
Canonical exit: 24 Aug 2021 (T+90)
10,700 shares@ US$3.85100.0% of flowCommon StockSEC:0001104659-21-073495:0
Canonical exit: 23 Aug 2021 (T+90)
47,063 shares@ US$6.40100.0% of flowCommon StockSEC:0001104659-21-022188:0
7,843 shares@ US$6.4086.3% of flowCommon StockSEC:0001104659-21-022185:0
1,000 shares@ US$8.0013.7% of flowCommon StockSEC:0001104659-21-022185:1
Canonical exit: 13 May 2021 (T+90)
47,063 shares@ US$6.40100.0% of flowCommon StockSEC:0001104659-21-022190:0
14 of 14 declarations
About GRI BIO, Inc.
GRI BIO, Inc. is a company listed on the XNAS market, specializing in the development of innovative biological solutions. It focuses on research and commercialization of products to enhance sustainability across various sectors.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
